The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial

H Richardson, D Johnston, J Pater, P Goss, H Richardson, D Johnston, J Pater, P Goss

Abstract

Several large phase III trials have demonstrated that tamoxifen-and more recently, raloxifene-can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (AIS) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has developed a randomized phase III study to determine the efficacy of an ai (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The NCIC CTG map.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the ais, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.

References

    1. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr. 2001;(30):5–15.
    1. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.
    1. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer: prospective data from the nurses’ health study. JAMA. 1993;270:338–43.
    1. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet. 1986;22:369–71.
    1. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–8.
    1. Kheifets LI, Matkin C. Industrialization, electromagnetic fields, and breast cancer risk. Environ Health Perspect. 1999;107 (suppl 1):145–54.
    1. Huff J, Boyd J, Barrett JC. Cellular and molecular mechanisms of hormonal carcinogenesis: environmental influences. Progress in Clinical and Biological Research series. Vol. 394.) New York: Wiley Liss; 1996: 1–479.
    1. Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin. 1999;49:138–44.
    1. Vatten LJ, Kvinnsland S. Pregnancy-related factors and risk of breast cancer in a prospective study of 29981 Norwegian women. Eur J Cancer. 1992;28A:1148–53.
    1. Kvinnsland S, Anker G, Dirix LY, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer. 2000;36:976–82.
    1. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in pre-menopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (epic) J Natl Cancer Inst. 2005;97:755–65.
    1. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst. 1996;88:291–6.
    1. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2000;98:1406–15.
    1. Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 2006;66:2476–82.
    1. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (igf-i), igf-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1566–73.
    1. Burroughs KD, Dunn SE, Barrett JC, Taylor JA. Insulin-like growth factor-i: a key regulator of human cancer risk? J Natl Cancer Inst. 1999;91:579–81.
    1. Prentice RL, Willett WC, Greenwald P, et al. Nutrition and physical activity and chronic disease prevention: research strategies and recommendations. J Natl Cancer Inst. 2004;96:1276–87.
    1. Kotsopoulos J, Olopado OI, Ghadirian P, et al. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2005;7:R833–43.
    1. Terry MB, Zhang FF, Kabat G, et al. Lifetime alcohol intake and breast cancer risk. Ann Epidemiol. 2006;16:230–40.
    1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.
    1. Boyd N, Byng J, Jong R, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87:670–5.
    1. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24:e49–50.
    1. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276–85. [Erratum in: N Engl J Med 2001;344:1804]
    1. Key T, Appleby P, Barnes I, Reeves G for the Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2000;94:606–16.
    1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.
    1. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (ibis-i): a randomised prevention trial. Lancet. 2002;360:817–24.
    1. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes—the nsabp study of tamoxifen and raloxifene (star) P-2 trial. JAMA. 2006;295:2727–41.
    1. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–69.
    1. Cuzick J, Forbes JF, Sestak I, et al. for the International Breast Cancer Intervention Study i Investigators. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized ibis-i trial. J Natl Cancer Inst. 2007;99:272–82.
    1. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: results of overview analysis of two phase iii trials. Arimidex Study Group. J Clin Oncol. 1996;14:2000–11.
    1. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453–61.
    1. Scott LJ, Wiseman LR. Exemestane. Drugs. 1999;58:675–80.
    1. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase iii randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18:1399–411.
    1. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the atac randomised trial. Lancet. 2002;359:2131–9. [Erratum in: Lancet 2002;360:1520]
    1. Coombes RC, Paridaens R, Jassem J, et al. First mature analysis of the Intergroup Exemestane Study (abstract LBA527) J Clin Oncol. 2006:24.
    1. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–70.
    1. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.
    1. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from ncic ctg ma.17. J Natl Cancer Inst. 2005;97:1262–71.
    1. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.
    1. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619–29.
    1. Gunson DE, Steele RE, Chau RY. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer. 1995;72:72–5.
    1. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (mnu)-induced mammary tumor model in Sprague–Dawley rats. Carcinogenesis. 1994;15:2775–80.
    1. Schieweck K, Bhatnagar AS, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993;44:633–6.
    1. Bhatnagar AS, Hausler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by cgs 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990;37:1021–7.
    1. O’Neill GP, Ford Hutchinson AW. Expression of messenger-rna for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 1993;330:156–60.
    1. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455–60.
    1. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–7.
    1. Khuder SA, Mutgi AB. Breast cancer and nsaid use: a meta-analysis. Br J Cancer. 2001;84:1188–92.
    1. Pesenti E, Masferrer JL, di Salle E. Effect of exemestane and celecoxib alone or in combination on dmba-induced mammary carcinoma in rats (abstract 445) Breast Cancer Res Treat. 2001;69:288.
    1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemo-prevention trial. N Engl J Med. 2005;352:1092–102. [Erratum in: N Engl J Med 2006;355:221]
    1. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–80.
    1. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580–5.
    1. Lewis CL, Kinsinger LS, Harris RP, Schwartz RJ. Breast cancer risk in primary care: implications for chemoprevention. Arch Intern Med. 2004;164:1897–903.
    1. Taylor R, Taguchi K. Tamoxifen for breast cancer chemo-prevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3:242–7.
    1. Salant T, Ganschow PS, Olopade OI, Lauderdale DS. “Why take it if you don’t have anything?” Breast cancer risk perceptions and prevention choices at a public hospital”. J Gen Intern Med. 2006;21:779–85.
    1. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. J Clin Oncol. 2002;20:3328–43.
    1. Haas JS, Kaplan CP, Gregorich SE, Perez–Stable EJ, Des JG. Do physicians tailor their recommendations for breast cancer risk reduction based on patient’s risk? J Gen Intern Med. 2004;19:302–9.
    1. Kaplan CP, Haas JS, Perez–Stable EJ, Des JG, Gregorich SE. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005;41:7–15.
    1. Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006;166:2260–5.
    1. Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97:715–23.
    1. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.
    1. United States, National Institutes of Health, National Cancer Institute (nci). Breast cancer risk assessment tool (Web resource). Bethesda: nci; n.d. [Available at: ; cited May 8, 2007]
    1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto: Canadian Cancer Society; 2006.
    1. Elmore JG, Fletcher SW. The risk of cancer risk prediction: “what is my risk of getting breast cancer? J Natl Cancer Inst. 2006;98:1673–5.
    1. Chlebowski RT, Anderson GL, Geller M, Col N. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin Breast Cancer. 2006;6(suppl 2):S58–64.
    1. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006;24:5305–12.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다